Kevin K. McDade

Kevin K. McDade

Auto-generated profile, based on publicly available information

Kevin K. McDade

Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA. ; Department of Science, The Pennsylvania State University, Shenango Campus, Sharon, PA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
HZHongXia Zheng
HongXia Zheng
AZAdriana Zeevi
Adriana Zeevi
ESErin Schuetz
Erin Schuetz
JLJatinder Lamba
Jatinder Lamba
KMKenneth McCurry
Kenneth McCurry
GBGilbert J. Burckart
Gilbert J. Burckart

27 May 2011 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
RDRoger S Day
Roger S Day
KMKevin K McDade
Kevin K McDade
UCUma R Chandran
Uma R Chandran
ALAlex Lisovich
Alex Lisovich
Thomas ConradsThomas Conrads
Thomas Conrads
GMG Larry Maxwell
G Larry Maxwell
Studies integrating transcriptomic data with proteomic data can illuminate the proteome more clearly than either separately. Integromic studies can deepen understanding of the dynamic complex regulatory relationship between the transcriptome and the proteome. Integrating these data dictates a reliable mapping between the identifier nomenclature resultant from the two high-throughput platforms. However, this kind of analysis is well known to be hampered by lack of standardization of identifier nomenclature among proteins, genes, and microarray probe sets. Therefore data integration may also play a role in critiquing the fallible gene identifications that both platforms emit.

1 July 2009 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
APAric A. Prather
Aric A. Prather
JCJudith E. Carroll
Judith E. Carroll
JFJacqueline M. Fury
Jacqueline M. Fury
KMKevin K. McDade
Kevin K. McDade
DRDiana Ross
Diana Ross
AMAnna L. Marsland
Anna L. Marsland

27 December 2006 in Transplantation
Verified
Journal Article
Closed access
DGDiana M. Girnita
Diana M. Girnita
SWSteven A. Webber
Steven A. Webber
RFRobert Ferrell
Robert Ferrell
GBGilbert J. Burckart
Gilbert J. Burckart
MBMaria Mori Mori Brooks
Maria Mori Mori Brooks
AZAdriana Zeevi
Adriana Zeevi
Allograft failure in African-Americans remains higher than in Caucasians. Single nucleotide polymorphisms (SNPs) have been associated with altered allograft outcomes. In this multi-center study we compared SNP frequencies in 364 pediatric heart recipients from three ethnic/racial groups: Caucasian (n = 243), African-American (n = 39), and Hispanic (n = 82). The target genes were: tumor necrosis factor-alpha, interleukin (IL)-10, IL-6, interferon (IFN)-gamma, vascular endothelial growth factor (VEGF), transforming growth factor-beta1, Fas, FasL, granzyme B, ABCB1, CYP3A5. Compared to Caucasians, African-Americans exhibited a higher prevalence of genotypes associated with low expression of IFN-gamma (24% vs. 45.7%, P < 0.001) and IL-10 (33% vs. 57.1%, P = 0.052). African-Americans also exhibited an increased prevalence of high IL-6 (82.9% vs. 38.1%; P < 0.001). VEGF -2578 C/C and -460 C/C genotypes were found more frequently in African-Americans and Hispanics as compared to Caucasians (P < 0.001). G/G genotype of Fas and T/T genotype of FasL were expressed more often by African-American recipients. The prevalence of Granzyme B (-295A/G) genotype was differentially distributed in the three groups. Compared with Caucasians, African-Americans were twice as likely to carry the ABCB1 2677 G/G genotype (78.6% vs. 33.7%, P < 0.0025), and they were more frequent carriers of the CYP3A5 *1/*1 genotype (35.7% vs. 0.6% in Caucasians and 7.2% in Hispanics; P < 0.001). African-Americans have a genetic background that may predispose to proinflammatory/lower regulatory environment, reduced drug exposure and immunosuppressive efficacy. In this ongoing multicenter study, these gene polymorphisms differences among ethnic/racial groups are being documented so that therapeutic strategies can be devised to optimize outcomes for pediatric transplant recipients.

1 January 2006 in Transplant Immunology
Verified
Journal Article
Closed access
JWJian Wang
Jian Wang
AZAdriana Zeevi
Adriana Zeevi
KMKenneth McCurry
Kenneth McCurry
ESErin Schuetz
Erin Schuetz
HZHongXia Zheng
HongXia Zheng
GBGilbert J. Burckart
Gilbert J. Burckart

1 March 2005 in Transplant Immunology
Verified
Journal Article
Closed access
HZH.X. Zheng
H.X. Zheng
AZA. Zeevi
A. Zeevi
KMK. McCurry
K. McCurry
ESE. Schuetz
E. Schuetz
SWS. Webber
S. Webber
GBG.J. Burckart
G.J. Burckart